| HOME >> BIOLOGY >> TECHNOLOGY |
SEATTLE, May 7 /PRNewswire/ -- Amnis Corporation and Gene Company, Ltd. announced today the completion of an agreement under which Gene Company will sell and service the Amnis ImageStream(R) system in China. Effective immediately, the scientific research communities in Hong Kong, Shanghai, Beijing and Guangzhou now have access to this important cell analysis technology.
"We are extremely pleased to have begun what we expect will be a valuable partnership with Gene Company. We are looking forward to working with them to expand the commercial presence of the ImageStream in China," said David Basiji, Ph.D., Amnis' President and CEO. "Gene Company has a strong presence in the major Chinese scientific markets and brings a distinguished history as a supplier to the partnership. We are quite confident that they will represent the ImageStream extremely well."
Dr. Cheung To, Chairman of Gene Company, added, "We envisage that distribution of the Amnis ImageStream system will remarkably empower pioneering labs with next generation microscopy and flow cytometry in a single platform to advance applications in drug discovery, molecular and cellular research and diagnostics in China. Gene Company has high confidence in Amnis and looks forward to a synergetic cooperation."
About Amnis:
Amnis Corporation, headquartered in Seattle, WA, develops, manufactures
and markets the ImageStream system for high speed imaging of cells in flow.
The system generates six high resolution microscopic images of cells as
they flow through the instrument at rates up to 300 cells per second. The
system is unique in its ability to image tens of thousands of cells in
minutes without the need to make slides. The IDEAS(R) image analysis
package, an integral part of the ImageStream system, is a highly
sophisticated yet easy to use tool for processing hundreds of thousands of
images at a time. IDEAS enables highly advanced research applications in
hematology, immunology, onc
'/>"/>
| SOURCE Amnis Corporation Copyright©2008 PR Newswire. All rights reserved |